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Summary
Vav1 is a guanine nucleotide exchange factor (GEF)
for Rho-family GTPases, which is activated by tyro-
sine phosphorylation following TCR stimulation. Vav1-
deficient mice have defects in positive and negative
selection of thymocytes as well as TCR-induced pro-
liferation in mature T cells, demonstrating a critical
role for Vav1 in transducing TCR signals. Binding of
phospholipids to the PH domain of Vav1 has been
proposed to regulate its GEF activity in vitro. To test
this model in vivo, we have generated mice carrying
a point mutation in the PH domain of Vav1, and we
show that they have defects in T cell development
and activation. We demonstrate that the mutation
affects the function of Vav1 as a GEF and perturbs
PI3K-dependent pathways downstream of Vav1. Un-
expectedly, the mutation selectively affects TCR-
induced proliferation of CD4+ but not CD8+ T cells,
demonstrating differences in the wiring of TCR sig-
naling pathways between the two lineages.
Introduction
Signals generated by the T cell antigen receptor (TCR)
are essential both for T cell development in the thymus
and for T cell activation in response to antigen. In the
thymus, signals from the pre-TCR control transition of
cells from the CD4−CD8− double-negative (DN) to the
CD4+CD8+ double-positive (DP) compartment, and sig-
nals from the TCR are required for positive selection
of DP thymocytes into mature CD4+CD8– or CD4–CD8+
single-positive (4SP or 8SP) cells, as well as for nega-
tive selection of autoreactive cells (Starr et al., 2003).
Vav1 is a 95 kDa cytoplasmic protein, which is rapidly
tyrosine phosphorylated following TCR stimulation
(Bustelo et al., 1992; Margolis et al., 1992). Vav1 has
a Dbl-homology (DH) domain that is characteristic of
guanine nucleotide exchange factors (GEFs) for Rho-
family GTPases (Tybulewicz, 2005). Vav1 has been
shown to function as a GEF for Rac1, Rac2, and RhoG
and to be activated by tyrosine phosphorylation
(Crespo et al., 1997; Han et al., 1997; Schuebel et al.,
1998). The importance of Vav1 in TCR signaling was*Correspondence: vtybule@nimr.mrc.ac.uk
1Present address: Institute of Genetics and Biophysics “Adriano
Buzzati Traverso,” CNR, via P. Castellino, 111, 80131 Napoli, Italy.demonstrated by defective positive and negative selec-
tion in Vav1-deficient DP thymocytes (Kong et al., 1998;
Turner et al., 1997) as well as reduced TCR-induced
IL-2 secretion and proliferation in Vav1-deficient T cells
(Fischer et al., 1995; Tarakhovsky et al., 1995; Zhang et
al., 1995). Furthermore, in the absence of Vav1, differen-
tiation of DN to DP thymocytes is partially compro-
mised, presumably because of reduced pre-TCR sig-
naling (Turner et al., 1997).
An invariant feature of all Rho-family GEFs is that the
catalytic DH domain is flanked by a pleckstrin homol-
ogy (PH) domain. Despite this uniformity of domain or-
ganization, the exact function of the PH domain remains
unclear and may be distinct for different Dbl-family pro-
teins (Hoffman and Cerione, 2002). For some members
of the Dbl family, but not others, the PH domain is re-
quired for in vitro GEF activity, and in some cases the
PH domain has been reported to bind to phospholipids
and modulate either the GEF activity of the associated
DH domain or plasma membrane recruitment.
In Vav1, mutation or deletion of the PH domain
causes loss of transformation ability in 3T3 cells and an
inability to hyperactivate the NF-AT transcription factor
following overexpression in Jurkat T cells, despite not
affecting in vitro GEF activity toward Rac1 (Billadeau et
al., 2000; Palmby et al., 2002; Zugaza et al., 2002). It
has been proposed that the PH domain of Vav1 binds
to the phospholipids phosphatidylinositol 4,5-bisphos-
phate (PIP2) and phosphatidylinositol 3,4,5-trisphos-
phate (PIP3) and that the binding of these two lipids
inhibits or augments the in vitro GEF activity of Vav1,
respectively (Han et al., 1998). Thus, mutation of argi-
nine 422 to glycine (R422G) within the PH domain,
which abolishes binding of both PIP2 and PIP3, was
predicted to result in a mutant protein that would be
hyperactive in vivo within unstimulated cells, since PIP2
could no longer inhibit it, and would be unresponsive
to TCR stimulation, since PIP3 would not be able to
activate it (Das et al., 2000).
This model for the function of the Vav1 PH domain
has been challenged by observations that in ectopically
expressed Vav1, mutations in the PH domain do not
result in a hyperactive GEF and do not affect its tyro-
sine phosphorylation (Zugaza et al., 2002). Further-
more, as this latter study points out, the PH domain of
Vav1 does not fit the consensus motif for PIP3 binding
to PH domains (Ferguson et al., 2000; Lietzke et al.,
2000). To date, there has been no analysis of the in vivo
role of the PH domain of Vav1 either in primary T cells
or in the absence of endogenous wild-type Vav1. To
address these issues, we have generated mice bearing
the Vav1R422G mutation, and we show that the effect of
the mutation is a partial inhibition of Vav1 function dur-
ing T cell development. In CD4+ T cells, the mutation
perturbs TCR-induced Rac1 activation, calcium flux,
and ERK activation. Most interestingly, the mutation se-
lectively affects TCR-induced proliferation of CD4+ but
not CD8+ T cells, despite a requirement for Vav1 in both
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naling pathways within the two cell types.
Results
Generation of Mice Bearing the Vav1R422G Allele
To investigate the role of the PH domain in the function
of Vav1, we generated mice expressing a mutated form
of Vav1 in which arginine 422 had been mutated to gly-
cine (R422G). R422 is a highly conserved residue in PH
domains, lying in the phospholipid binding pocket. The
same R422G mutation was used previously to abolish
the ability of PIP2 and PIP3 to bind to Vav1 in vitro (Han
et al., 1998). We chose to use a knockin approach to
make the mutation, as this is most likely to give correct
physiological levels of expression, in terms of both tis-
sue specificity and kinetics.
Using homologous recombination in PC3 ES cells,
we introduced the R422G mutation into exon 13 of the
Vav1 gene (Figure 1A). PC3 ES cells are derived from a
transgenic 129S4 mouse expressing the Cre recombi-
nase only in haploid spermatids (O’Gorman et al.,
1997). At the same time, we also introduced a silent
mutation in codon 418 to create a novel TaqI site, allow-
ing the mutation to be subsequently followed by South-
ern blotting (Figure 1B). Finally, the targeting vector
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1Figure 1. Generation of Mice Bearing the
Vav1R422G Allele
(A) Diagram of the genomic structure of the
wild-type Vav1 gene before targeting, the
targeting vector TV-PL12, and the two pos-
sible targeted alleles generated in the ES cell
genome: Vav1R422Gneo containing both the
loxP-flanked neo gene in intron 9 and the
R422G mutation in exon 13, and Vav1neo
containing only the neo gene. Subsequent
recombination between loxP sites catalyzed
by the Cre recombinase in the mouse re-
sulted in the deletion of the neo gene, leav-
ing behind a single loxP site in intron 9,
and thus generating two possible alleles:
Vav1R422G bearing the R422G mutation and
the loxP site, and Vav1lox carrying only the
loxP site. Introduction of the neo gene into
intron 9 was identified by Southern blotting
of genomic DNA cut by EcoRV and probed
with a 137 bp fragment located in intron 16
(probe A). Introduction of the R422G muta-
tion was identified by Southern blotting of
genomic DNA cut by TaqI and probed with a
819 bp fragment located in intron 13 (probe
B). Predicted sizes of hybridizing bands are
shown. Black boxes above the line represent
exons 3–6 of Vav1, black triangles represent
loxP sites, hatched boxes show location of
probes. R, EcoRI; S, SpeI; T, TaqI; V, EcoRV;
X, XhoI. Not all TaqI sites are shown.
(B) Southern blot of genomic DNA from ES
cells of the indicated genotypes cut with
either EcoRV (top) or TaqI (bottom) and
probed as indicated.
(C) Immunoblot of cell lysates from purified
CD4+ and CD8+ T cells from the lymph nodes
of Vav1loxP/loxP and Vav1R422G/R422G mice. The blots were probed with an antibody specific for Vav1 and then reprobed with an anti-
body specific for ERK2 to control for equal loading. Quantitation of seven independent measurements showed that the level of Vav1 in
Vav1R422G/R422G mice as a percentage of the level of Vav1 in Vav1loxP/loxP or Vav1+/+ mice was 87% ± 14% in CD4+ T cells and 75% ± 19% in
CD8+ T cells.ontained a neo gene flanked by loxP sites (floxed)
ithin intron 9 to allow selection for uptake of DNA.
av1R422Gneo/+ ES clones were used to generate chim-
ric mice. During subsequent breeding of the chimeras,
xpression of Cre within the male germline resulted in
he deletion of the floxed neo gene, resulting in the
av1R422G allele, which contains the R422G mutation as
ell as a single loxP site within intron 9. To control for
otential effects of the remaining loxP site, we also
sed Vav1neo/+ ES cells to generate mice containing the
av1loxP allele, but no mutation at R422 (Figures 1A
nd 1B).
Vav1R422G/R422G and Vav1loxP/loxP mice were viable
nd grossly normal. Immunoblot analysis demon-
trated that both strains of mice expressed levels of
av1 identical to each other and to that of Vav1+/+ mice
oth in CD4+ and CD8+ T cells (Figure 1C and data not
hown). For many experiments, Vav1loxP/loxP mice were
sed as controls; however, to date no differences have
een observed between these mice and Vav1+/+ mice.
efective Thymic Development
n Vav1R422G/R422G Mice
ice deficient in Vav1 (Vav1−/−) show characteristic de-
elopmental abnormalities in the thymus (Fischer et al.,
995; Tarakhovsky et al., 1995; Turner et al., 1997;
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265Zhang et al., 1995). They have a partial block at the
transition from DN to DP thymocytes, resulting in a
2-fold reduction in the number of DP cells. This is most
likely because Vav1 transduces pre-TCR signals. Fur-
thermore, in the absence of Vav1, there is a strong
block between DP and 4SP or 8SP thymocytes. We and
others have previously shown that this is most likely
due to a block in positive selection of both class I- and
class II-restricted TCRs, suggesting that Vav1 may
transduce the TCR signals that lead to positive selec-
tion of thymocytes (Kong et al., 1998; Turner et al.,
1997).
To evaluate whether the PH domain of Vav1 is re-
quired for its function within thymic development, we
compared the numbers of DN, DP, 4SP, and 8SP cells
in Vav1loxP/loxP, Vav1R422G/R422G, and Vav1−/− mice.
Vav1R422G/R422G mice consistently showed a small re-
duction in the number of DP cells relative to controls,
though this was never as large as the reduction seen in
Vav1−/− mice (Figures 2A and 2B). This suggested that
the R422G mutation may perturb the pre-TCR check-
point. To investigate this further, we subdivided DN
cells according to the expression of CD44 and CD25
and enumerated the number of cells in the resultantFigure 2. Partial Block in T Cell Development
in Vav1R422G/R422G Mice
(A) Dot plots showing CD4 and CD8 levels
on thymocytes from mice of the indicated
genotypes. Numbers show percentages of
cells falling into the marked gates. Histo-
gram shows CD5 expression on CD4+CD8+
double-positive (DP) thymocytes gated as on
dot plots, from mice of the following geno-
types: Vav1loxP/loxP (bold line), Vav1R422G/R422G
(thin line), and Vav1−/− (shaded histogram).
(B) Graph showing mean number of double-
negative (DN, CD4−CD8−), DP, CD4+ single-
positive (4SP), and CD8+ single-positive
(8SP) thymocytes in mice of the indicated
genotypes, gated as in (A). Ten mice of each
genotype were analyzed. Error bars repre-
sent SEM. Statistically significant differences
are indicated: *p < 0.0001, **p < 0.05. The
number of DP cells was consistently re-
duced in Vav1R422G/R422G mice compared
with Vav1loxP/loxP mice. While this did not
reach statistical significance in the experi-
ment shown, analysis of a combination of
two experiments showed a significant re-
duction (p < 0.05).
(C) Expression of CD44 and CD25 on DN
cells. Numbers show percentages of cells
falling into the indicated gates.
(D) Graph showing mean (±SEM) numbers of
DN cells subdivided into DN1 (CD44+CD25−),
DN2 (CD44+CD25+), DN3 (CD44−CD25+), and
DN4 (CD44−CD25−), gated as in (C). Statis-
tically significant differences are indicated:
*p < 0.05.
(E) The Vav1R422G allele does not overcome
the developmental block in Rag1−/− mice.
Dot plots show expression of CD4 and CD8
on thymocytes from Rag1−/− mice that were
either Vav1+/+ or Vav1R422G/R422G as indi-
cated.DN1, DN2, DN3, and DN4 subsets (Figures 2C and 2D).
Vav1R422G/R422G thymocytes showed a significant de-
crease in the number of DN4 cells relative to Vav1loxP/loxP
mice, consistent with a partial block in development
between the DN3 and DN4 stages, suggesting that
Vav1R422G is partially compromised in its ability to
transduce a pre-TCR signal.
The level of CD5 expression in DP thymocytes ap-
pears to be sensitive to changes in TCR or pre-TCR
signaling (Azzam et al., 2001). We previously showed
that the level of CD5 expression on Vav1−/− DP thymo-
cytes is significantly reduced (Turner et al., 1997), con-
sistent with defective TCR signaling. Vav1R422G/R422G
DP cells also showed a significant reduction in CD5
expression, albeit not as large as found in Vav1−/−
cells (Figure 2A), suggesting that Vav1R422G is partially
defective in transducing a TCR signal. Similarly to
CD5, the expression of CD2 was also reduced in
Vav1R422G/R422G mice relative to Vav1loxP/loxP mice,
though not by as much as Vav1-deficient mice (not
shown), suggesting that like CD5, the expression of
CD2 may also be regulated by TCR signaling. In con-
trast, the expression of CD4, CD8, TCRβ, and CD3 on
DP, 4SP, and 8SP cells was unaffected.
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showed a small, albeit significant, reduction in the num-
ber of 4SP cells, though once again not as large a re-
duction as seen in Vav1-deficient mice (Figure 2B). In
contrast, the number of 8SP cells was not significantly
reduced. There was no change in the numbers of CD4+
or CD8+ T cells in the spleen or lymph nodes of
Vav1R422G/R422G mice (not shown). Taken together,
these results suggested the R422G mutation might
have partially affected positive selection, though per-
haps only of 4SP cells.
Defective Positive Selection in Vav1R422G/R422G Mice
To investigate further the potential defect in positive se-
lection, we bred Vav1R422G/R422G mice with transgenic
mice expressing either class I- or class II-restricted
TCRs. Additionally, these mice were also bred to be
Rag1 deficient, in order to eliminate rearrangement of
any other TCR genes. F5 is a TCR specific for a peptide
from influenza nuclear protein presented by H2-Db, and
in Rag1-deficient mice transgenic for the F5 TCR
(F5Rag1−/−), thymic development is entirely skewed
into the CD8+ lineage (Mamalaki et al., 1993). Similarly,
in Vav1R422G/R422GF5Rag1−/− mice, thymic development
was skewed into the CD8+ lineage, and the percentage
of 8SP thymocytes was not significantly different from
that in Vav1+/+F5Rag1−/− mice (Figure 3A).
AND is a class II-restricted TCR specific for a peptide
from pigeon cytochrome c presented by I-Ek (Kaye et
al., 1989). T cell development in Rag1-deficient mice
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Selection of CD4+ Single-Positive Thymo-
cytes in Vav1R422G/R422G Mice
(A) Expression of CD4 and CD8 on thymo-
cytes from F5Rag1−/− mice that were either
Vav1+/+ or Vav1R422G/R422G as indicated.
Numbers indicate percentage of cells falling
into the 8SP gate. Graph shows mean
(±SEM) percentage of 8SP thymocytes.
There was no significant difference between
the means of the two genotypes.
(B) Expression of CD4 and CD8 on thymo-
cytes from ANDRag1−/− mice that were either
Vav1+/+ or Vav1R422G/R422G as indicated.
Numbers indicate percentage of cells falling
into the 4SP gate. Graph shows mean
(±SEM) percentage of 4SP thymocytes. The
mean percentages were significantly dif-
ferent, p = 0.0003.
(C) Graph showing mean (±SEM) percentage
of 4SP thymocytes that expressed a particu-
lar Vβ gene, from mice of the indicated geno-
types. Statistically significant differences are
indicated: *0.01 < p < 0.05; **0.001 < p <
0.01; ***p < 0.001.ransgenic for the AND TCR (ANDRag1−/−) is entirely
kewed into the CD4+ lineage (Figure 3B). While in
av1R422G/R422GANDRag1−/− mice, thymic development
as also skewed into the CD4+ lineage, the percentage
f 4SP thymocytes was significantly reduced relative to
av1+/+ANDRag1−/− mice (Figure 3B). Taken together,
hese results show that the Vav1R422G mutation selec-
ively perturbs positive selection of CD4+ but not CD8+
cells. In previous work, we showed that Vav1 was
bsolutely required for the positive selection of both
lass I- and class II-restricted T cells (Turner et al.,
997). For example, in Vav1−/−F5Rag1−/− mice, no 8SP
ells develop at all. Thus, while the Vav1R442G muta-
ion perturbs the positive selection of CD4+ T cells, it is
ess severe than a complete absence of Vav1 protein.
efective Negative Selection in Vav1R422G/R422G Mice
av1 is also required for normal negative selection of
hymocytes (Turner et al., 1997). To evaluate whether
he PH domain is required for this function, we exam-
ned negative selection by endogenous superantigens.
n B10.BR mice, proteins encoded by mouse mammary
umor proviruses (Mtv loci) are presented in association
ith the class II molecule I-Ek and result in the deletion
f CD4+ thymocytes expressing Vβ5, 11, and 12, but
ot Vβ8 (Simpson et al., 1993). Flow cytometric analysis
f Vav1−/− and Vav1R422G/R422G mice that had been
ackcrossed to B10.BR showed specific absence of
D4+ T cells expressing Vβ5, 11, and 12, in comparison
o B10 mice that do not undergo Mtv-mediated deletion
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Vav1R422G/R422G mice was greater than in Vav1−/− mice,
though both genotypes showed less deletion than
B10.BR (Vav1+/+) mice. In contrast, Vβ8-expressing
CD4+ T cells, which do not bind the Mtv superantigens
present in B10.BR, were unaffected in all genotypes.
Taken together, these data show that as with positive
selection, negative selection of thymocytes is less effi-
cient in mice expressing Vav1R422G, but is not as com-
promised as in Vav1-deficient animals.
Vav1R422G Cannot Rescue the Developmental
Block in Rag1−/− Mice
It has been proposed that the binding of PIP2 to the PH
domain of Vav1 inhibits its exchange activity, and that
in vivo Vav1R422G, which is unable to bind PIP2, would
be hyperactive (Han et al., 1998). In a separate study, it
has been shown that a transgenic mouse expressing a
constitutively active allele of Rac1 is able to overcome
the block at the pre-TCR selection checkpoint in
Rag1−/− mice (Gomez et al., 2000). We reasoned that if
Vav1R422G was a hyperactive GEF, this should result
in increased levels of activated Rac1 and hence should
also be able to rescue the pre-TCR developmental
block in Rag1−/− mice. However, we found that this was
not the case. As in Rag1−/− mice, thymic development
in Vav1R422G/R422GRag1−/− mice was completely ar-
rested at the DN stage (Figure 2E). Thus, the behavior
of Vav1R422G is not equivalent to a constitutively
active Rac1 GTPase. However, it is possible that
Vav1R422G is hyperactive but does not generate suffi-
ciently high levels of Rac1-GTP to drive differentiation
to DP cells, either because it cannot access all Rac1
molecules, or because of the action of negative regula-
tors such as RacGAPs.
Defective TCR-Induced Proliferation
of Vav1R422G/R422G CD4+ but Not CD8+ T Cells
Since a hallmark of the phenotype of Vav1-deficient
mice is reduced TCR-induced proliferation of both
CD4+ and CD8+ T cells (Costello et al., 1999; Fischer et
al., 1995; Tarakhovsky et al., 1995; Zhang et al., 1995),
we examined the effect of the Vav1R422G mutation on
this process. We found that in response to anti-CD3
alone or anti-CD3 and anti-CD28, Vav1R422G/R422G CD4+
T cells proliferated less well than control cells but better
than Vav1−/− cells (Figures 4A and 4B). In contrast, while
the proliferation of Vav1−/− CD8+ T cells was greatly re-
duced, the proliferation of Vav1R422G/R422G CD8+ T cells
was indistinguishable from control cells, even at subop-
timal doses of anti-CD3 (Figures 4A and 4B).
Using CFSE to monitor cell division, we found that
the overall reduction in proliferation of Vav1R422G/R422G
CD4+ T cells was caused both by a delay in cell-cycle
entry (not shown) and in a reduced fraction of cells en-
tering cell cycle (Figure 4C). In contrast, the fraction
of Vav1R422G/R422G CD8+ T cells entering cell cycle was
unchanged relative to control cells, despite a large re-
duction in cell-cycle entry in Vav1−/− CD8+ T cells. Com-
mitment to cell division can be seen as early as 12 hr
poststimulation by monitoring TCR-induced increase in
cell size (blasting). Using this measure, we found that
fewer Vav1R422G/R422G CD4+ T cells had blasted com-pared to control cells, though once again Vav1−/− CD4+
T cells were more affected (Figure 4D). Taken together,
these data show that the R422G mutation compro-
mises the ability of Vav1 to transduce TCR signals lead-
ing to the division of CD4+ T cells, while not affecting
responses in CD8+ T cells, despite a requirement for
Vav1 in transducing these TCR signals in both lineages.
Reduced TCR-Induced Calcium Flux and ERK
Activation in Vav1R422G/R422G CD4+ and CD8+ T Cells
To understand the role of the PH domain of Vav1 in
more detail, we analyzed the biochemical signaling
pathways induced by TCR stimulation. Furthermore, in
view of the differential effect of the R422G mutation on
TCR-induced proliferation of CD4+ T cells compared to
CD8+ T cells, we sought to find differences in the TCR
signaling pathways between these cell types that might
explain this result.
We and others have previously shown that in CD4+
T cells, Vav1 transduces TCR signals, leading to the
induction of an intracellular calcium flux and to the acti-
vation of the ERK MAP kinases (Costello et al., 1999;
Fischer et al., 1998; Holsinger et al., 1998). Thus, we
examined the effect of the R422G mutation on these
two pathways. TCR-induced calcium flux was reduced
in Vav1R422G/R422G CD4+ T cells relative to control cells;
however, there was an even greater reduction in Vav1−/−
CD4+ T (Figure 5A). We also analyzed the TCR-induced
calcium flux in CD8+ T cells. In view of the normal TCR-
induced proliferation (Figures 4A and 4C), we were sur-
prised to find a reduced TCR-induced calcium flux in
Vav1R422G/R422G CD8+ T cells, although this reduction
was less severe than in Vav1R422G/R422G CD4+ T cells
(Figure 5A). Once again, Vav1−/− CD8+ T cells showed
a greater reduction than cells expressing the R422G
mutant.
Examination of TCR-induced ERK activation showed
that the R422G mutation caused a reduction in ERK
activation relative to control cells in both CD4+ and
CD8+ cells (Figures 6A and 6B). Once again, the re-
sponse of Vav1R422G/R422G cells was intermediate be-
tween that of control and Vav1−/− cells. Thus, the
R422G mutation partially affects the ability of Vav1 to
transduce TCR signals, leading to calcium flux and ERK
activation, and it does this in both CD4+ and CD8+ T
cells.
The Vav1R422G Mutation Affects PI3K-Dependent
Pathways Downstream of Vav1
In earlier work, we showed that in double-positive thy-
mocytes, Vav1 transduces TCR signals to the induction
of a calcium flux and to the activation of ERK by regu-
lating the activation of PLCγ1 (Reynolds et al., 2002,
2004). Furthermore, we showed that Vav1 activates
PLCγ1 via phosphoinositide 3-kinase (PI3K)-dependent
and -independent pathways. To determine whether this
is also true in T cells and to assess which of these path-
ways is perturbed by the Vav1R422G mutation, we first
examined the TCR-induced activation of Akt as a surro-
gate for PI3K activation. We found that in the absence
of Vav1, TCR-induced phosphorylation of Akt on serine
473 was greatly reduced in both CD4+ and CD8+ T cells
(Figures 6A and 6B). Furthermore, in cells expressing
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268Figure 4. Defective TCR-Induced Prolifera-
tion in CD4+ but Not CD8+ T Cells from
Vav1R422G/R422G Mice
(A) Graph showing mean (±SEM) prolifera-
tion of sorted CD4+ or CD8+ lymph node T
cells from mice with the indicated genotypes
as measured by incorporation of 3H-thymi-
dine. Cells were stimulated with platebound
anti-CD3 antibody (6 g/ml) in the presence
or absence of soluble anti-CD28 antibody
(10 g/ml). Results are representative of five
(CD4+) or three (CD8+) independent experi-
ments.
(B) Graph showing mean (±SEM) prolifera-
tion of sorted CD4+ and CD8+ lymph node T
cells from mice with the indicated genotypes
as measured by incorporation of 3H-thymi-
dine. Cells were stimulated with the indi-
cated concentrations of anti-CD3 antibody
in the presence of soluble anti-CD28 anti-
body (10 g/ml).
(C) Graphs showing CFSE fluorescence of
CD4+ or CD8+ lymph node T cells that had
been labeled with CFSE and cultured for 36
hr with platebound anti-CD3 antibody (6
g/ml) and soluble anti-CD28 antibody (10
g/ml). Data are shown for cells from mice
of the following genotypes: Vav1loxP/loxP
(shaded histogram), Vav1R422G/R422G (bold
line), and Vav1−/− (thin line). The fraction of
CD4+ T cells that had entered division was
58% in control, 28% in Vav1R422G/R422G, and
3% in Vav1−/− cultures. In the same cultures,
the fraction of CD8+ T cells that had entered
division was 28% in control, 26% in
Vav1R422G/R422G, and 2% in Vav1−/−. Results
are representative of three independent
experiments.
(D) Graphs showing forward scatter as a
measure of cells size from lymph node cells
cultured for 12 hr with platebound anti-CD3
antibody (6 g/ml) and soluble anti-CD28 an-
tibody (10 g/ml). Results are shown gated
on CD4+ T cells from Vav1loxP/loxP (shaded
histogram), Vav1R422G/R422G (bold line), and
Vav1−/− (thin line) mice.Vav1R422G, phosphorylation of Akt was also defective
compared to control cells, though the reduction was
not as great as in Vav1−/− cells. Since the TCR-induced
phosphorylation of Akt on serine 473 is dependent on
PI3K, as shown by the inhibitory effect of Ly294002, a
PI3K inhibitor (Figure 7A), we conclude that the activa-
tion of PI3K is probably defective in both CD4+ and
CD8+ T cells expressing Vav1R422G.
The TCR-induced activation of ERK in T cells and
thymocytes is largely dependent on the activation of
PLCγ1 (Ebinu et al., 2000; Reynolds et al., 2004). Vav1-
deficient thymocytes have a defect in TCR-induced
ERK activation, which is also mainly due to a failure to
activate PLCγ1 (Reynolds et al., 2004). Since we have
shown that in thymocytes the activation of PLCγ1 is
partially dependent on PI3K, we reasoned that PI3K
should also play a role in ERK activation. In agreement
with this, treatment of Vav1loxP/loxP CD4+ T cells with
Ly294002 partially inhibits TCR-induced ERK activation
(Figure 7B).
In Vav1-deficient thymocytes, the TCR-induced asso-
ciation of PLCγ1 with the adaptor protein SLP-76 is de-
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sective, and this pathway is PI3K independent (Rey-
olds et al., 2002). Vav1 may influence this association
y regulating phosphorylation of LAT on key tyrosine
esidues (Reynolds et al., 2004). We examined this
athway in T cells by detecting TCR-induced phos-
horylation of LAT on Y175. As previously seen in thy-
ocytes, in CD4+ T cells this phosphorylation was also
I3K independent, since it was unaffected by treatment
ith Ly294002 (Figure 7C). However, in contrast to the
esult in thymocytes, we found that both in CD4+ and
D8+ T cells, phosphorylation of LAT on Y175 was
argely unaffected either by the absence of Vav1 or by
he R422G mutation (Figures 6A and 6B). Thus, unlike
he situation in thymocytes, in T cells Vav1 is not re-
uired to transduce TCR signals leading to the phos-
horylation of LAT. However, we note that in some ex-
eriments, we saw a slight reduction in pY175-LAT at
he 3 and 10 min time points in both CD4+ and CD8+
av1−/− T cells, suggesting that in the absence of Vav1,
AT phosphorylation may not be sustained for as long
s in wild-type cells (Figures 6A and 6B and data not
hown).
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269Figure 5. TCR-Induced Vav1 Phosphoryla-
tion and Calcium Flux in Vav1R422G/R422G T
Cells
(A) Graphs show the mean ratio of Indo-1
violet/blue fluorescence, a measure of intra-
cellular [Ca2+] as a function of time in CD4+
or CD8+ lymph node cells gated as in the
dot plots from Vav1loxP/loxP (black line),
Vav1R422G/R422G (gray line), and Vav1−/− (light
gray line) mice. Arrow indicates time at
which the cells were stimulated. Numbers on
dot plots represent percentages of cells
within gated areas.
(B) Vav1loxP/loxP and Vav1R422G/R422G CD4+
lymph node T cells were coated with anti-
CD3 and anti-CD28 antibodies and then
stimulated by crosslinking with a secondary
antibody for the indicated time, or left un-
stimulated (0 min). Phosphorylation of Vav1
on tyrosine 174 was measured with an anti-
body against pY174-Vav1; equal loading was
confirmed by immunoblottting with an anti-
body against Vav1. Note there is a nonspe-
cific band visible just above pY174-Vav1.Reduced Rac1 Activation Despite Normal Tyrosine
Phosphorylation of Vav1R422G
Binding of phospholipids to the PH domain of Vav1 has
been proposed to modulate its GEF activity. In particu-
lar, binding of PIP3 has been shown to promote tyrosine
phosphorylation of Vav1 in vitro and hence its activa-
tion (Han et al., 1998). To evaluate this model in vivo,
we measured TCR-induced phosphorylation of Vav1 on
tyrosine 174, a residue whose phosphorylation is re-
quired for activation of Vav1’s exchange activity (Agha-
zadeh et al., 2000; Lopez-Lago et al., 2000). We found
no significant difference in the accumulation of pY174-
Vav1 in Vav1R422G/R422G CD4+ T cells compared to con-
trols (Figure 5B). We also assayed TCR-induced Rac1
activation in CD4+ T cells expressing Vav1R422G. We
found that in Vav1R422G/R422G T cells, Rac1 activation
was reduced relative to control cells, though it was still
higher than the residual activation of Rac1 in Vav1−/−
cells (Figure 6A). Taken together, these data suggest
that the R422G mutation has partially compromised the
ability of Vav1 to activate Rac1, consistent with the idea
that binding of ligands to the PH domain of Vav1 may
modulate its GEF activity. However, we found no evi-
dence to suggest that the PH domain modulates phos-
phorylation of Vav1, at least on tyrosine 174.
A Role for PI3K in TCR-Induced Activation of Rac1
If the binding of PIP3 to the PH domain of Vav1 regu-
lates its exchange activity toward Rac1, then TCR-
induced activation of Rac1 should be sensitive to inhib-
itors of PI3K. To test this, we treated control andVav1R422G/R422G CD4+ T cells with Ly294002. We found
that Ly294002 partially inhibited TCR-induced Rac1
activation in control cells (Figure 7C). As described
earlier, T cells expressing Vav1R422G have decreased
TCR-induced Rac1 activation. However, treatment with
Ly294002 decreased this further still. In contrast, the
phosphorylation of Vav1 on Y174 was unaffected by
treatment with Ly294002 (Figure 7A). Taken together,
these results show that there is a PI3K-dependent
pathway leading from the TCR to Rac1 activation. This
may be via PIP3 binding to the PH domain of Vav1
and activating its GEF activity; however, it does not ap-
pear to involve modulation of phosphorylation on Y174
of Vav1. Furthermore, these results show that there
must also be another mechanism by which PI3K trans-
duces signals to Rac1 activation, since activation of
the GTPase was further inhibited by Ly294002 in
Vav1R422G/R422G T cells.
Discussion
Using homologous recombination, we have generated
a mouse strain bearing a single amino acid mutation,
R422G, in the PH domain of Vav1. Such a “knockin”
approach resulted in an accurate matching of expres-
sion level of the mutant Vav1 with that of wild-type
Vav1, which would have been difficult using a conven-
tional transgenic approach. Analysis of mice express-
ing Vav1R422G showed that the mutation partially com-
promises the function of Vav1. As in Vav1-deficient
mice, transition of cells through the pre-TCR check-
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270Figure 6. The R422G Mutation Affects Multi-
ple TCR Signaling Pathways in Both CD4+
and CD8+ T Cells
CD4+ (A) or CD8+ (B) lymph node T cells of
the indicated genotypes were stimulated for
the indicated times with anti-CD3 and anti-
CD28 antibodies as described in Figure 5B.
Rac1 activation was evaluated by pulling
down active GTP-loaded Rac1 with a GST
fusion protein containing the Rac binding
domain of Pak1 (GST-Pak1-RBD) and blot-
ting with anti-Rac1 antiserum. Equal quanti-
ties of Rac1 in the extracts were confirmed
by immunoblotting a fraction of the total cell
lysates taken before the GST-Pak1-RBD
pull-down. Total cell lysates were also immu-
noblotted with antisera specific for phos-
photyrosine 204 of ERK2 (p-ERK2), phos-
phoserine 473 of Akt (pS473-Akt), and
phosphotyrosine 175 of LAT (pY175-LAT).
Equal loading was confirmed by reprobing
blots with antiserum specific for ERK2, Akt,
and LAT. Activation of the cells was checked
by probing blots with antiserum specific for
phosphotyrosine (pTyr).point and positive and negative selection of DP thymo-
cytes was less efficient. Furthermore, in mature T cells,
TCR-induced proliferation, calcium flux, and ERK acti-
vation were also defective. In all cases the effect of the
R422G mutation was less than that of a complete defi-
ciency, demonstrating that the mutation only partially
perturbs the function of Vav1. Most notably, the muta-
tion selectively affected the positive selection and TCR-
induced proliferation of CD4+ SP thymocytes and CD4+
T cells, respectively, despite a clear requirement for
Vav1 in both CD4+ and CD8+ lineages.
Han et al. proposed that binding of PIP2 and PIP3 to
the PH domain of Vav1 inhibits or activates its GEF ac-
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wivity, respectively (Han et al., 1998). In particular, they
roposed that binding of PIP3 to the PH domain would
educe the affinity of the PH domain for the DH domain,
hereby allowing tyrosine phosphorylation of Vav1 and
inding of Rac1 to the DH domain (Das et al., 2000).
urthermore, using the R422G mutation, which elimi-
ates phospholipid binding to the PH domain, they
howed that in vitro, Vav1R422G is no longer inhibited
r activated by PIP2 or PIP3, respectively. They pre-
icted that Vav1R422G would be hyperactive in unstim-
lated cells, because it could not be inhibited by PIP2,
nd would no longer be activatable because PIP3
ould not bind. However, this model has been chal-
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271Figure 7. PI3K Is Both Upstream and Down-
stream of Vav1
CD4+ lymph node T cells of the indicated ge-
notypes were stimulated with anti-CD3 and
anti-CD28 antibodies as described in Figure
5B in either the absence (N) or presence of
the PI3K inhibitor Ly294002. Levels of
pY174-Vav1, pS473-Akt, pERK2, and pY175-
LAT and activation of Rac1 were evaluated as
described in Figure 6A.lenged on the grounds that the PH domain of Vav1 does
not fit the consensus for PIP3 binding PH domains (Zu-
gaza et al., 2002).
We find no evidence of hyperactivity of Vav1R422G.
In unstimulated T cells, the level of Rac1-GTP is no
higher in Vav1R422G/R422G cells compared to wild-type
(Figures 6A and 7C). In addition, the Vav1R422G muta-
tion was unable to overcome the pre-TCR checkpoint
block in Rag1−/− mice (Figure 2E), in contrast to the ef-
fect of an activated Rac1 transgene (Gomez et al.,
2000). Thus, at least within the cell types tested, our
data do not support the idea that PIP2 inhibits the GEF
activity of Vav1 by binding to the PH domain.
We also found no evidence to support the proposal
that PIP3 binding to the PH domain of Vav1 regulates
its tyrosine phosphorylation, since the phosphorylation
of Y174 was unaffected either by the R422G mutation
or by treatment with Ly294002.
In contrast, our results do not rule out the possibility
that PIP3 binding to the PH domain activates the GEF
activity of Vav1, since both the Vav1R422G mutation
and treatment of CD4+ T cells with a PI3K inhibitor de-
creases TCR-induced Rac1 activation. However, the ef-
fect of the Vav1R422G mutation is not as severe as that
of a complete absence of Vav1, implying that the
Vav1R422G protein can still be activated and that it is
still capable of transducing TCR signals to Rac1 activa-
tion. In addition, there is also residual TCR-induced
Rac1 activation in T cells treated with Ly294002. Taken
together, these results suggest that while Vav1 may
be activated by PIP3, it must also be activated by a
PIP3-independent mechanism, e.g., tyrosine phosphory-
lation. Furthermore, because Ly294002 decreases TCR-
induced Rac1 activation in cells expressing Vav1R422G,
there must be PIP3-dependent pathway(s) leading to
Rac1 activation that are independent of R422. These
might be through an indirect effect of PIP3 on Vav1, by
PIP regulation of the related Vav2 and Vav3 molecules,3or by effects of PIP3 on non-GEF proteins upstream of
Rac1.
Interestingly, in the presence of PI3K inhibitor, TCR-
induced Rac1 activation was lower in cells expressing
Vav1R422G compared to control cells, demonstrating
that the PH domain of Vav1 may also be regulated by
ligands other than PIP3 (Figure 7C). One possibility for
such a ligand is PIP2, whose binding may promote Vav1
GEF activity rather than inhibiting it. A final resolution
of the issue of which ligands bind to the PH domain of
Vav1, and of how these may regulate GEF activity, will
require information on the structure of the DH and PH
domains of Vav1 in the presence and absence of puta-
tive ligands.
In earlier work, we showed that in thymocytes Vav1
transduces TCR signals to the activation of PLCγ1 (and
hence calcium flux) through PI3K-dependent and -inde-
pendent pathways (Reynolds et al., 2002). The PI3K-
dependent pathway may involve PIP3 binding to and
activating Tec-family kinases, which in turn phosphoryl-
ate PLCγ1. In this study, we show that in both CD4+
and CD8+ T cells, TCR-induced Akt phosphorylation, a
surrogate for PI3K activation, is reduced in cells defi-
cient in Vav1 or in cells expressing Vav1R422G. Thus in
T cells, Vav1 (and more particularly its PH domain) is
required for TCR-induced activation of PI3K. It remains
unclear how Vav1 activates PI3K, but it may be through
Rac1, since the GTPase has been shown to bind to
PI3K (Bokoch et al., 1996; Tolias et al., 1995; Zheng et
al., 1994). Thus, the effect of the Vav1R422G mutation
on PI3K activation would be a consequence of reduced
GEF activity and hence decreased TCR-induced Rac1
activation.
In view of this, we propose that an in vivo function of
the PH domain of Vav1 is to regulate its GEF activity,
potentially in response to binding of PIP3 or other li-
gands. By regulating GEF activity and hence Rac1 ac-
tivation, the PH domain affects Rac1-induced PI3K ac-
Immunity
272tivation and thus the PI3K-dependent pathway leading
to PLCγ1 activation, calcium flux, and ERK activation.
We note that such a signaling scheme potentially
places PI3K both upstream and downstream of Vav1,
suggesting the possibility of a positive-feedback loop
that may in part function to amplify the activation of
Vav1.
In thymocytes, Vav1 also functions in a PI3K-inde-
pendent pathway, by regulating the association of
PLCγ1 with the adaptor proteins SLP-76 and LAT, prob-
ably by controlling the phosphorylation of LAT on key
tyrosine residues 175, 195, and 235 (Reynolds et al.,
2004). In the current study, we examined this pathway
in CD4+ and CD8+ T cells but found that Vav1-deficient
cells had largely normal TCR-induced LAT phosphory-
lation, demonstrating a difference in wiring of signaling
pathways between thymocytes and T cells. Limitations
in cell numbers precluded directly evaluating the effect
of a Vav1 deficiency on the association of PLCγ1 with
LAT and SLP-76.
The most unexpected finding in this study was that
the R422G mutation selectively perturbs TCR-induced
selection and proliferation of CD4+ but not CD8+ T cells,
despite a critical role for Vav1 in both lineages. This
result demonstrates that there are differences in TCR
signaling pathways between the two cell types. Studies
of a number of TCR signaling pathways showed that
both CD4+ and CD8+ T cells from Vav1R422G/R422G mice
showed decreased TCR-induced calcium flux and acti-
vation of ERK and Akt. We also found decreased Rac1
activation in Vav1R422G/R422G CD4+ T cells but were un-
able to analyze this in CD8+ T cells, due to limited cell
numbers. Further studies are needed to discover the
reasons for the different effect of the R422G mutation
on the two T cell lineages.
In conclusion, we have shown that in vivo the PH do-
main of Vav1 is required for the TCR-induced regulation
of its exchange activity. As a result, mice bearing a mu-
tation in this domain show selective defects in T cell
development and activation. Most notably, the muta-
tion affects activation of CD4+ but not CD8+ T cells,
pointing to a difference in TCR signaling pathways be-
tween these two cell lineages.
Experimental Procedures
Mice
To generate mice bearing the Vav1R422G allele, a targeting vector
TV-PL12 was prepared consisting of an 8786 bp DNA fragment of
the Vav1 gene from 129/Sv mouse genomic DNA, extending from
an SpeI site in intron 2 to a XhoI site in intron 16. A loxP-flanked
neo gene from pHR68 (D. Duboule) was inserted into an EcoRI site
in intron 9. In addition, the sequence of exon 13 was altered by
site-directed mutagenesis to change codon 422 from AGG (Arg) to
GGG (Gly), as well as simultaneously altering codon 418 from TCA
to TCG, which creates a novel TaqI site while leaving the amino
acid sequence unchanged. The targeting DNA was also flanked by
a thymidine kinase gene (Tybulewicz et al., 1991) to the 3# side.
The targeting vector was linearized and electroporated into PC3
ES cells (O’Gorman et al., 1997), and G418-resistant clones were
selected by standard methods (Tybulewicz et al., 1991). ES cell
clones in which the targeting vector had undergone homologous
recombination into the Vav1 gene were identified by Southern blot-
ting of genomic DNA cut with EcoRV, using a 137 bp fragment
(probe A) located in intron 16 of Vav1, 3# of the targeting vector
sequence, generated by PCR using the following oligonucleotides:
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s#-GGAATTACAGATGTACATCACAAAATTT-3# and 5#-GATATCCC
GG-TAGAATGTGCCTCTGC-3#. This probe identified a 5.4 kb
coRV fragment in the wild-type Vav1 gene and a 4.5 kb fragment
n the targeted allele. To screen for introduction of the point muta-
ions in exon 13, ES cell genomic DNA was digested with TaqI,
outhern blotted, and probed with a 819 bp fragment (probe B)
unning from exon 13 to exon 14 generated by PCR using the fol-
owing oligonucleotides: 5#-ACCAGTCTCTGGCTAACTA-3# and 5#-
GAGGCTTTGAGGTCGTAA-3#. This probe detected a 1448 bp
ragment in the wild-type Vav1 gene and a 769 bp fragment in the
av1 allele bearing the point mutations. Correct targeting was con-
irmed by extensive restriction mapping of the targeted Vav1 allele
sing both 5# and 3# flanking probes.
Two ES clones bearing the neo gene in intron 9 of Vav1 as well
s the R422G mutation (Vav1R422Gneo/+) and one ES clone bearing
he neo gene only (Vav1neo/+) were injected into C57BL/6 blasto-
ysts by standard techniques to generate chimeric mice. Male chi-
eras were bred to 129S8 female mice, and progeny derived from
he ES cells were screened for loss of neo following Cre-mediated
ecombination between loxP sites by Southern blotting of EcoRV-
ut genomic DNA with the intron 16 probe described before (Figure
A). A single loxP site was left in intron 9 after Cre-mediated dele-
ion. Female mice bearing either the Vav1R422G (Vav1tm2Tyb) allele or
he Vav1loxP (Vav1tm3Tyb) allele (Figures 1A and 1B) were crossed
o 129S8 male mice to breed away the Prm1-Cre transgene, and
ubsequent generations were either maintained on the 129S8
ackground or backcrossed to B10.BR for five generations. Mice
earing the Vav1R422G or Vav1loxP alleles were routinely genotyped
y PCR to detect the presence of the loxP site in intron 9 using the
ollowing oligonucleotides: 5#-ACCTGCTGAGCCCGGTCATCA-3#
nd 5#-TGTTAGCTCTTTGAGAACATT-3#. This PCR amplifies a 400
p fragment from wild-type DNA and a 475 bp fragment from
av1R422G or Vav1loxP alleles. To distinguish the Vav1R422G or Vav1loxP
lleles, we Southern blotted genomic DNA cut with TaqI using
robe B as described earlier. The Vav1R422G/R422G strain was estab-
ished from two independent ES clones. Both lines of mice showed
he same phenotype in terms of thymic development, T cell prolif-
ration, and TCR-induced calcium flux (not shown), thus strongly
upporting that the observed phenotype of Vav1R422G/R422G mice
as due to the R422G mutation.
The generation of mice carrying a mutation disrupting the Vav1
ene (Vav1tm1Tyb/tm1Tyb; Vav1−/−) on both a 129S8 and B10.BR back-
round has been previously described (Turner et al., 1997). Mice
earing the F5 TCR transgene (Mamalaki et al., 1993) and the AND
CR transgene (Kaye et al., 1989) and deficient for Rag1 (Rag1−/−)
Spanopoulou et al., 1994) were obtained from D. Kioussis, B.
tockinger, and D. Baltimore, respectively. All mice were analyzed
etween 6 and 12 weeks of age and were age and sex matched
ithin each experiment.
low Cytometry
ingle-cell suspensions from thymus, spleen, and lymph nodes
ere stained in PBS, 0.5% BSA, 0.01% NaN3, containing the ap-
ropriate, pretitered antibodies. To reduce nonspecific binding,
ells were pretreated with anti-CD16(2.4G2). Analysis was done on
FACScan or a FACSCalibur (all BD Biosciences, CA) and sorting
n a MoFlo (Cytomation, Inc., Oxon, UK). Analysis was carried out
sing CELLQuest software (BD Biosciences). All plots shown are
epresentative of at least three independent experiments.
The following antibodies were purchased from BD Biosciences:
ntiCD3-bio, anti-CD4-PE, anti-CD8α-PE, FITC-labeled anti-CD8α,
CD5, -TCRβ, -Vβ5, -Vβ8, -Vβ11, -Vβ12. To enumerate early thymic
ubsets, thymocytes were stained with anti-CD44-FITC, anti-CD25-
E, anti-B220-CyChrome, anti-CD3-bio, anti-Gr1-bio, anti-Mac1-
io (all from BD Biosciences), anti-CD4-Tricolor, and anti-CD8α-Tri-
olor (Caltag), followed by Streptavidin-Red670 (GIBCO-BRL). To
istinguish early thymocyte subsets, the CD25 and CD44 expres-
ion of cells failing to stain in the FL3 channel was plotted.
roliferation Assay
orted CD4+ or CD8+ lymph node T cells were washed, resus-
ended in proliferation medium (RPMI 1640 medium, 10% fetal calf
erum, 1 mM sodium pyruvate, and 5 × 10−5 M 2-mercaptoethanol),
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273and plated in 96-well flat-bottomed plates at 106 cells/ml, 0.1 ml/
well. Some wells contained immobilized anti-CD3 antibody
(145.2C11) and soluble anti-CD28 antibody (37-51). Cells were cul-
tured for 39–42 hr at 37°C, pulsed with 3H-thymidine (0.5 Ci/well;
Amersham) for the final 4–18 hr of culture, and harvested, and in-
corporated radioactivity was quantitated.
For analysis of proliferation using CFSE, disaggregated lymph
nodes were stained for 5 min with 0.5 M CFSE in Dulbecco’s PBS
without phenol red, washed twice in proliferation medium, and
plated in 96-well flat-bottomed plates as described above. Some
wells contained immobilized anti-CD3 antibody (145.2C11) and sol-
uble anti-CD28 antibody (37-51). At various time points, cell cul-
tures were stained with anti-CD4 and anti-CD8 antibodies and ana-
lyzed by flow cytometry. To calculate the percentage of cells that
had been triggered to divide (progenitor frequency), we determined
the number of cells that had not divided (n0) or that had gone
through 1, 2, … i divisions (n1, n2, … ni). In experiments analyzed,
no cells had divided more than five times, so divisions above this
were ignored. Progenitor frequency (P) was calculated as follows:
P =
∑
i=1
5
(ni2i)
∑
i=0
5
(ni2i)
Calcium Flux
Calcium flux in lymph node cells labeled with anti-CD4-PE and anti-
CD8-FITC, anti-CD3 (10 g/ml), and Indo-1-AM (4 g/ml, Sigma)
was measured using an LSR flow cytometer (BD Biosciences) as
previously described (Reynolds et al., 2002).
Stimulation of CD4+ T Cells for Biochemical Analysis
Lymph nodes were disaggregated in air-buffered Iscove’s modified
Dulbecco’s medium (AB-IMDM; GIBCO-BRL). CD4+ T cells were
purified by negative selection either by using Mouse CD4 subset
columns (R&D Systems, Abingdon, UK) or by using Streptavidin
M280 Dynabeads (Dynal Biotech) to remove cells stained with bioti-
nylated antibodies to B220, CD8, Mac1, Gr1, and DX5. CD8+ T cells
were purified using an autoMacs (Miltenyi Biotec) to positively se-
lect cells labeled with anti-CD8α Microbeads (Miltenyi Biotec) ac-
cording to the manufacturer’s instructions. For stimulations, the cells
were preincubated with hamster anti-mouse CD3 (mAb 145.2C11)
and anti-mouse CD28 (mAb 37-51) both at 10 g/ml for 20 min in
AB-IMDM on ice, washed, and then incubated in AB-IMDM for
5 min at 37°C before crosslinking of the antibodies with goat anti-
Armenian hamster IgG antiserum (75 g/ml; Jackson Immuno-
Research). Where PI3K inhibitors were used, thymocytes were pre-
incubated with Ly294002 (10 M; Sigma) at 37°C for 30 min prior
to standing on ice for 5 min. Preincubation with anti-CD3 and anti-
CD28 on ice then proceeded as above, still in the presence of inhib-
itor. Subsequent crosslinking of the antibodies also occurred in the
presence of inhibitor. For control samples where no inhibitor was
used, an equivalent volume of DMSO carrier was added.
Immunoblotting
Cells were stimulated in AB-IMDM for the specified times and stim-
ulation stopped by the addition of an equal volume of 2× Cell Lysis
Buffer (Cell Signaling Technology) including 2 mM sodium ortho-
vanadate, 2 mM DTT, and 1:50 [vol/vol] protease inhibitor cocktail
(P8340; Sigma-Aldrich). Cell lysates were cleared by centrifugation
at 15,340 × g for 15 min at 4°C, and an equal volume of 2× Laemmli
sample buffer was added before boiling for 3 min. SDS-PAGE and
immunoblotting were carried out by standard procedures. The fol-
lowing antibodies were used for immunoblotting: anti-Rac1 (23A8),
anti-phosphotyrosine (4G10, both from Upstate Biotechnology),
anti ERK1/2 (K-23), anti phospho-ERK (E-4), anti Vav1 (C-14) from
Santa Cruz Biotechnology, anti-phosphoserine473-Akt, anti-Akt,
and anti-phosphotyrosine171-human LAT (equivalent to pY175 mu-
rine LAT; all from Cell Signaling Technology), anti-phosphotyro-
sine174-Vav1 (gift from X. Bustelo), and anti-LAT (gift from M.
Turner). For immunoblots, antibody binding was revealed with goat
anti-mouse IgG-HRP for mouse mAb, or goat anti-rabbit IgG-HRP(Cell Signaling Technology) for rabbit polyclonal Ab. Blots probed
with anti-phospho-ERK, anti-phospho-Akt, anti-phospho-LAT, and
anti-phosphotyrosine174-Vav1 antibodies were stripped and re-
probed with antibodies to anti-ERK, anti-Akt, anti-LAT, and anti-
Vav1 to control equal loading across lanes.
Quantitation of Vav1
CD4+ and CD8+ lymph node T cells were purified by flow cytometric
cell sorting (MoFlo, Cytomation), and then lysed in RIPA buffer (20
mM Tris-Cl [pH 7.4], 140 mM NaCl, 2 mM EDTA, 50 mM NaF, 0.5%
NP40, 0.1% SDS, 0.5% deoxycholate). Cell lysates were cleared
and analyzed by SDS-PAGE and immunoblotting by standard pro-
cedures, except that blocking of immunoblots and binding of pri-
mary antibodies was carried out in Odyssey Blocking Buffer (Li-Cor
Biotechnology) and antibody binding was revealed with goat anti-
rabbit IgG-AlexaFluor 680 (Molecular Probes). Blots were scanned
using an Odyssey Infrared Imager (Li-Cor Biotechnology) and ana-
lyzed using the manufacturer’s software. Vav1 levels were normal-
ized to the expression of ERK2.
Rac1 Activation
For analysis of Rac1 activation, cells were stimulated in AB-IMDM,
lysed as described above, and cleared by centrifugation at
15,340 × g at 4°C for 2 min. Activated Rac1 was isolated as pre-
viously described (Reynolds et al., 2002).
Statistical Analysis
All statistical comparisons were carried out using the nonparamet-
ric two-tailed Mann-Whitney test.
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